References
- Chaplin D.J., Acker B. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. International Journal of Radiation Oncology, Biology, Physics 1987; 13: 579–585
- Hill S., Williams K.B., Denekamp J. Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. European Journal of Cancer and Clinical Oncology 1989; 25: 1419–1424
- Horsman M.R., Christensen K.L., Overgaard J. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. International Journal of Hyperthermia 1989; 5: 123–136
- Kallman R.F., Silini G., Van Putten L.M. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumours. Journal of the National Cancer Institute 1967; 39: 539–549
- Kalmus J., Okunieff P., Vaupel P. Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSaII tumors. Cancer Research 1990; 50: 15–19
- Sapirstein L.A. Regional blood flow by fractional distribution of indicators. American Journal of Physiology 1958; 193: 161–168
- Zwi L.J., Baguley B.C., Gavin J.B., Wilson W.R. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. Journal of the National Cancer Institute 1989; 81: 1005–1013